Top

Published in:

01-06-2020 | Pituitary Adenoma | Original Research

Long-term outcomes of hypofractionated stereotactic radiotherapy for refractory functional pituitary adenoma

Authors: Alexander D. Sherry, Mohamed H. Khattab, Mark C. Xu, Patrick Kelly, Joshua L. Anderson, Guozhen Luo, Andrea L. Utz, Lola B. Chambless, Anthony J. Cmelak, Albert Attia

Published in: Journal of Radiation Oncology | Issue 1-2/2020

Abstract

Objective

Refractory functional pituitary adenomas are often treated with single-session stereotactic radiosurgery (SRS) or conventionally fractionated intensity-modulated radiotherapy (IMRT). While single-fraction SRS offers convenience and short time to biochemical remission, large tumors with cranial nerve or chiasmatic involvement often preclude single-fraction SRS, and toxicity may be worse following single-fraction SRS compared with IMRT. The purpose of our study was to explore the long-term outcomes of a unique hypofractionated stereotactic radiotherapy (HSRT) regimen delivered in 2–5 fractions.

Methods

After approval, we studied 16 consecutive patients treated with HSRT for refractory functional pituitary adenoma. Study endpoints included local control, biochemical control, and toxicity. Descriptive statistics summarized endpoints and clinicopathologic factors.

Results

Sixteen patients with adrenocorticotropic hormone secretion (n = 9, 56%), growth hormone secretion (n = 4, 25%), and prolactin secretion (n = 3, 19%) were studied with a median follow-up time after HSRT of 10 years (IQR 2–14 years). Patients were treated with two (n = 8), three (n = 1), or five (n = 7) fractions to median dose of 20.5 Gy (range 16–32 Gy). HSRT was well-tolerated with no acute side effects greater than CTCAE grade 1. Local control was 100%, and biochemical control at last follow-up was 58%. Over 142 years patient-years, no instances of optic neuropathy, secondary malignancy, malignant transformation, radionecrosis, cavernous sinus cranial neuropathy, or cerebrovascular complications were noted.

Conclusion

HSRT for refractory pituitary adenoma is well-tolerated with long-term local and biochemical control comparable with single-fraction SRS or IMRT. Prospective studies should evaluate whether HSRT provides non-inferior biochemical control and improved toxicity compared with single-fraction SRS.

Ezzat S, Asa SL, Couldwell WT, Barr CE, Dodge WE, Vance ML, McCutcheon IE (2004) The prevalence of pituitary adenomas: a systematic review. Cancer 101:613–619. https://doi.org/10.1002/cncr.20412 CrossRefPubMed

Dolecek T, Propp J, Stroup N, Kruchko C (2012) CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009. Neuro-Oncology 14(Suppl 5):v1–v49. https://doi.org/10.1093/neuonc/nos218 CrossRefPubMedPubMedCentral

Molitch ME (2017) Diagnosis and treatment of pituitary adenomas: a review. JAMA - J Am Med Assoc 317:516–524. https://doi.org/10.1001/jama.2016.19699 CrossRef

Mehta GU, Lonser RR (2017) Management of hormone-secreting pituitary adenomas. Neuro-Oncology 19:762–773. https://doi.org/10.1093/neuonc/now130 CrossRefPubMed

Kreutzer J, Buslei R, Wallaschofski H, Hofmann B, Nimsky C, Fahlbusch R, Buchfelder M (2008) Operative treatment of prolactinomas: indications and results in a current consecutive series of 212 patients. Eur J Endocrinol 158:11–18. https://doi.org/10.1530/EJE-07-0248 CrossRefPubMed

Starke RM, Raper DMS, Payne SC, Vance ML, Oldfield EH, Jane JA (2013) Endoscopic vs microsurgical transsphenoidal surgery for acromegaly: outcomes in a concurrent series of patients using modern criteria for remission. J Clin Endocrinol Metab 98:3190–3198. https://doi.org/10.1210/jc.2013-1036 CrossRefPubMed

Ciric I, Zhao JC, Du H, Findling JW, Molitch ME, Weiss RE, Refetoff S, Kerr WD, Meyer J (2012) Transsphenoidal surgery for Cushing disease: experience with 136 patients. Neurosurgery 70:70–81. https://doi.org/10.1227/NEU.0b013e31822dda2c CrossRefPubMed

Johnston PC, Kennedy L, Hamrahian AH, Sandouk Z, Bena J, Hatipoglu B, Weil RJ (2017) Surgical outcomes in patients with Cushing’s disease: the Cleveland clinic experience. Pituitary 20:430–440. https://doi.org/10.1007/s11102-017-0802-1 CrossRefPubMed

Ding D, Starke RM, Sheehan JP (2014) Treatment paradigms for pituitary adenomas: defining the roles of radiosurgery and radiation therapy. J Neuro-Oncol 117:445–457. https://doi.org/10.1007/s11060-013-1262-8 CrossRef

10.

Loeffler JS, Shih HA (2011) Radiation therapy in the management of pituitary adenomas. [Review]. J Clin Endocrinol Metab 96:1992–2003. https://doi.org/10.1210/jc.2011-0251 CrossRefPubMed

11.

Mitsumori M, Shrieve DC, Alexander E, Kaiser UB, Black PML, Loeffler JS (1998) Initial clinical results of linac-based stereotactic radiosurgery and stereotactic radiotherapy for pituitary adenomas. Int J Radiat Oncol Biol Phys 42:573–580. https://doi.org/10.1016/S0360-3016(98)00256-9 CrossRefPubMed

12.

Chan M, Rogers CL, Anderson B, Khuntia D (2016) Benign brain tumors: meningiomas and vestibular schwannomas. In: Gunderson L, Tepper J, Bogart J (eds) Clinical radiation oncology. Fourth. Elsevier Inc., Philadelphia, pp 483–501CrossRef

13.

Zeman E (2016) The biological basis of radiation oncology. In: Gunderson L, Tepper J, Bogart J (eds) Clinical radiation oncology. Fourth. Elsevier Inc., Philadelphia, pp 2–40CrossRef

14.

Chadwick KH, Leenhouts HP (1973) A molecular theory of cell survival. Phys Med Biol 18:78–87. https://doi.org/10.1088/0031-9155/18/1/007 CrossRefPubMed

15.

Kellerer AM, Rossi HH (1974) The theory of dual radiation action. Curr Top Radiat Res 8:85–158

16.

Fowler JF (2010) 21 years of biologically effective dose. Br J Radiol 83:554–568. https://doi.org/10.1259/bjr/31372149 CrossRefPubMedPubMedCentral

17.

Kong DS, Lee JI, Do HL KWK, Hyung JS, Nam DH, Park K, Jong HK (2007) The efficacy of fractionated radiotherapy and stereotactic radiosurgery for pituitary adenomas: long-term results of 125 consecutive patients treated in a single institution. Cancer 110:854–860. https://doi.org/10.1002/cncr.22860 CrossRefPubMed

18.

Park HR, Park KW, Lee JM, Kim JH, Jeong SS, Kim JW, Chung HT, Kim DG, Paek SH (2019) Frameless fractionated gamma knife radiosurgery with ICON™ for large metastatic brain tumors. J Korean Med Sci 34:e57. https://doi.org/10.3346/jkms.2019.34.e57 CrossRefPubMedPubMedCentral

19.

Yomo S, Hayashi M, Nicholson C (2012) A prospective pilot study of two-session gamma knife surgery for large metastatic brain tumors. J Neuro-Oncol 109:159–165. https://doi.org/10.1007/s11060-012-0882-8 CrossRef

20.

Khattab M, Sherry A, Whitaker R, Wharton D, Weaver K, Chambless L, Cmelak A, Attia A (2019) A retrospective cohort study of longitudinal audiologic assessment in single and fractionated stereotactic radiosurgery for vestibular schwannoma. Neurosurgery pii:nzy219. https://doi.org/10.1093/neuros/nyz219

21.

Niranjan A, Flickinger JC (2008) Radiobiology, principle and technique of radiosurgery. Prog Neurol Surg 21:32–42. https://doi.org/10.1159/000156557 CrossRefPubMed

22.

Kondziolka D, Shin SM, Brunswick A, Kim I, Silverman JS (2015) The biology of radiosurgery and its clinical applications for brain tumors. Neuro-Oncology 17:29–44. https://doi.org/10.1093/neuonc/nou284 CrossRefPubMed

23.

Hall EJ, Brenner DJ (1993) The radiobiology of radiosurgery: rationale for different treatment regimes for AVMs and malignancies. Int J Radiat Oncol Biol Phys 25:381–385. https://doi.org/10.1016/0360-3016(93)90367-5 CrossRefPubMed

24.

Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG (2009) Research electronic data capture (REDCap)-a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 42:377–381. https://doi.org/10.1016/j.jbi.2008.08.010 CrossRefPubMed

25.

Cahan W, Woodard H (1948) Sarcoma arising in irradiated bone; report of 11 cases. Cancer 1:3–29CrossRefPubMed

26.

Fowler JF (1989) The linear-quadratic formula and progress in fractionated radiotherapy. Br J Radiol 62:679–675. https://doi.org/10.1259/0007-1285-62-740-679 CrossRefPubMed

27.

Erridge SC, Conkey DS, Stockton D, Strachan MWJ, Statham PFX, Whittle IR, Grant R, Kerr GR, Gregor A (2009) Radiotherapy for pituitary adenomas: long-term efficacy and toxicity. Radiother Oncol 93:597–601. https://doi.org/10.1016/j.radonc.2009.09.011 CrossRefPubMed

28.

Brada M, Rajan B, Traish D, Ashley S, Holmes-Sellors PJ, Nussey S, Uttley D (1993) The long-term efficacy of conservative surgery and radiotherapy in the control of pituitary adenomas. Clin Endocrinol 38:571–578. https://doi.org/10.1111/j.1365-2265.1993.tb02137.x CrossRef

29.

Tishler RB, Loeffler JS, Lunsford LD, Duma C, Alexander E, Kooy HM, Flickinger JC (1993) Tolerance of cranial nerves of the cavernous sinus to radiosurgery. Int J Radiat Oncol Biol Phys 27:215–221. https://doi.org/10.1016/0360-3016(93)90230-S CrossRefPubMed

30.

Mayo C, Martel MK, Marks LB, Flickinger J, Nam J, Kirkpatrick J (2010) Radiation dose-volume effects of optic nerves and chiasm. Int J Radiat Oncol Biol Phys 76:S28–S35. https://doi.org/10.1016/j.ijrobp.2009.07.1753 CrossRefPubMed

31.

Pham CJ, Chang SD, Gibbs IC, Jones P, Heilbrun MP, Adler JR, Lunsford LD, Friedman WA, Pollock BE, Gutin PH, Pendl G (2004) Preliminary visual field preservation after staged CyberKnife radiosurgery for perioptic lesions. Neurosurgery 54:799–810. https://doi.org/10.1227/01.NEU.0000114261.18723.6A CrossRefPubMed

32.

Adler JR, Gibbs IC, Puataweepong P, Chang SD (2006) Visual field preservation after multisession CyberKnife radiosurgery for perioptic lesions. Neurosurgery 59:2442–2454. https://doi.org/10.1227/01.NEU.0000223512.09115.3E CrossRef

33.

Killory BD, Kresl JJ, Wait SD, Ponce FA, Porter R, White WL (2009) Hypofractionated CyberKnife radiosurgery for perichiasmatic pituitary adenomas: early results. Neurosurgery 64:A19–A25. https://doi.org/10.1227/01.NEU.0000341630.42160.18 CrossRefPubMed

34.

Iwata H, Sato K, Tatewaki K, Yokota N, Inoue M, Baba Y, Shibamoto Y (2011) Hypofractionated stereotactic radiotherapy with CyberKnife for nonfunctioning pituitary adenoma: high local control with low toxicity. Neuro-Oncology 13:916–922. https://doi.org/10.1093/neuonc/nor055 CrossRefPubMedPubMedCentral

35.

Liao HI, Wang CC, Wei KC, Chang CN, Hsu YH, Lee ST, Huang YC, Chen HC, Hsu PW (2014) Fractionated stereotactic radiosurgery using the Novalis system for the management of pituitary adenomas close to the optic apparatus. J Clin Neurosci 21:111–115. https://doi.org/10.1016/j.jocn.2013.03.024 CrossRefPubMed

36.

Milano MT, Grimm J, Soltys SG, Yorke E, Moiseenko V, Tomé WA, Sahgal A, Xue J, Ma L, Solberg TD, Kirkpatrick JP, Constine LS, Flickinger JC, Marks LB, El Naqa I (2018) Single- and multi-fraction stereotactic radiosurgery dose tolerances of the optic pathways. Int J Radiat Oncol Biol Phys S0360-3016:30125–30121. https://doi.org/10.1016/j.ijrobp.2018.01.053 CrossRef

37.

Glatstein E (2008) Hypofractionation, long-term effects, and the alpha/beta ratio. Int J Radiat Oncol Biol Phys 72:11–12. https://doi.org/10.1016/j.ijrobp.2008.07.006 CrossRefPubMed

38.

Glatstein E (2011) The omega on alpha and beta. Int J Radiat Oncol Biol Phys 81:319–320. https://doi.org/10.1016/j.ijrobp.2011.01.011 CrossRefPubMed

39.

Park C, Papiez L, Zhang S, Story M, Timmerman RD (2008) Universal survival curve and single fraction equivalent dose: useful tools in understanding potency of ablative radiotherapy. Int J Radiat Oncol Biol Phys 70:847–852. https://doi.org/10.1016/j.ijrobp.2007.10.059 CrossRefPubMed

40.

Jackson IMD, Noren G (1999) Gamma knife radiosurgery for pituitary tumours. Bailliere’s Best Pract Res Clin Endocrinol Metab 13:461–469. https://doi.org/10.1053/beem.1999.0033 CrossRef

41.

Shin M, Kurita H, Sasaki T, Tago M, Morita A, Ueki K, Kirino T (2000) Stereotactic radiosurgery for pituitary adenoma invading the cavernous sinus. J Neurosurg 93:2–5. https://doi.org/10.3171/jns.2000.93.supplement CrossRefPubMed

42.

Amichetti M, Amelio D, Minniti G (2012) Radiosurgery with photons or protons for benign and malignant tumours of the skull base: a review. Radiat Oncol 7:210. https://doi.org/10.1186/1748-717X-7-210 CrossRefPubMedPubMedCentral

43.

Roche P-H, Régis J, Dufour H, Fournier H-D, Delsanti C, Pellet W, Grisoli F, Peragut J-C (2000) Gamma knife radiosurgery in the management of cavernous sinus meningiomas. J Neurosurg 93:68–73. https://doi.org/10.3171/jns.2000.93.supplement_3.0068 CrossRefPubMed

44.

van den Bergh ACM, van den Berg G, Schoorl MA, Sluiter WJ, van der Vliet AM, Hoving EW, Szabó BG, Langendijk JA, Wolffenbuttel BHR, Dullaart RPF (2007) Immediate postoperative radiotherapy in residual nonfunctioning pituitary adenoma: beneficial effect on local control without additional negative impact on pituitary function and life expectancy. Int J Radiat Oncol Biol Phys 67:863–869. https://doi.org/10.1016/j.ijrobp.2006.09.049 CrossRefPubMed

45.

Minniti G, Osti M, Jaffrain-Rea ML, Esposito V, Cantore G, Maurizi Enrici R (2007) Long-term follow-up results of postoperative radiation therapy for Cushing’s disease. J Neuro-Oncol 84:79–84. https://doi.org/10.1007/s11060-007-9344-0 CrossRef

46.

Sheehan JP, Pouratian N, Steiner L, Laws ER, Vance ML (2011) Gamma knife surgery for pituitary adenomas: factors related to radiological and endocrine outcomes. J Neurosurg 114:303–309. https://doi.org/10.3171/2010.5.jns091635 CrossRefPubMed

47.

Pollock BE, Cochran J, Natt N, Brown PD, Erickson D, Link MJ, Garces YI, Foote RL, Stafford SL, Schomberg PJ (2008) Gamma knife radiosurgery for patients with nonfunctioning pituitary adenomas: results from a 15-year experience. Int J Radiat Oncol Biol Phys 70:1325–1329. https://doi.org/10.1016/j.ijrobp.2007.08.018 CrossRefPubMed

48.

Voges J, Kocher M, Runge M, Poggenborg J, Lehrke R, Lenartz D, Maarouf M, Gouni-Berthold I, Krone W, Muller RP, Sturm V (2006) Linear accelerator radiosurgery for pituitary macroadenomas: a 7-year follow-up study. Cancer 107:1355–1364. https://doi.org/10.1002/cncr.22128 CrossRefPubMed

49.

Littley MD, Shalet SM, Beardwell CG, Ahmed SR, Applegate G, Sutton ML (1989) Hypopituitarism following external radiotherapy for pituitary tumours in adults. QJM 70:145–160. https://doi.org/10.1093/oxfordjournals.qjmed.a068308 CrossRefPubMed

50.

Barber SM, Teh BS, Baskin DS (2016) Fractionated stereotactic radiotherapy for pituitary adenomas: single-center experience in 75 consecutive patients. Neurosurgery 79:406–417. https://doi.org/10.1227/NEU.0000000000001155 CrossRefPubMed

51.

Gopalan R, Schlesinger D, Vance ML, Laws E, Sheehan J (2011) Long-term outcomes after gamma knife radiosurgery for patients with a nonfunctioning pituitary adenoma. Neurosurgery 69:284–293. https://doi.org/10.1227/NEU.0b013e31821bc44e CrossRefPubMed

52.

Höybye C, Grenbäck E, Rähn T, Degerblad M, Thorén M, Hulting AL (2001) Adrenocorticotropic hormone-producing pituitary tumors: 12- to 22-year follow-up after treatment with stereotactic radiosurgery. Neurosurgery 49:284–292. https://doi.org/10.1097/00006123-200108000-00008 CrossRefPubMed

53.

Kim JO, Ma R, Akagami R, McKenzie M, Johnson M, Gete E, Nichol A (2013) Long-term outcomes of fractionated stereotactic radiation therapy for pituitary adenomas at the BC cancer agency. Int J Radiat Oncol Biol Phys 87:528–533. https://doi.org/10.1016/j.ijrobp.2013.06.2057 CrossRefPubMed

54.

Castinetti F, Nagai M, Dufour H, Kuhn J-M, Morange I, Jaquet P, Conte-Devolx B, Regis J, Brue T (2007) Gamma knife radiosurgery is a successful adjunctive treatment in Cushing’s disease. Eur J Endocrinol 156:91–98. https://doi.org/10.1530/eje.1.02323 CrossRefPubMed

55.

Pouratian N, Sheehan J, Jagannathan J, Laws ER, Steiner L, Vance ML (2006) Gamma knife radiosurgery for medically and surgically refractory prolactinomas. Neurosurgery 59:255–266. https://doi.org/10.1227/01.NEU.0000223445.22938.BD CrossRefPubMed

56.

Roberts BK, Ouyang DL, Lad SP, Chang SD, Harsh GR, Adler JR, Soltys SG, Gibbs IC, Katznelson L (2007) Efficacy and safety of CyberKnife radiosurgery for acromegaly. Pituitary 10:19–25. https://doi.org/10.1007/s11102-007-0004-3 CrossRefPubMed

57.

Minniti G, Osti MF, Niyazi M (2016) Target delineation and optimal radiosurgical dose for pituitary tumors. Radiat Oncol 11:135. https://doi.org/10.1186/s13014-016-0710-y CrossRefPubMedPubMedCentral

Title: Long-term outcomes of hypofractionated stereotactic radiotherapy for refractory functional pituitary adenoma
Authors: Alexander D. Sherry
Mohamed H. Khattab
Mark C. Xu
Patrick Kelly
Joshua L. Anderson
Guozhen Luo
Andrea L. Utz
Lola B. Chambless
Anthony J. Cmelak
Albert Attia
Publication date: 01-06-2020
Publisher: Springer Berlin Heidelberg
Keywords: Pituitary Adenoma
Radiotherapy
Published in: Journal of Radiation Oncology / Issue 1-2/2020
Print ISSN: 1948-7894
Electronic ISSN: 1948-7908
DOI: https://doi.org/10.1007/s13566-020-00416-0

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Objective

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1-2/2020

Analysis of setup uncertainties and determine the variation of the clinical target volume (CTV) to planning target volume (PTV) margin for various tumor sites treated with three-dimensional IGRT couch using KV-CBCT

Radiofrequency radiation: carcinogenic and other potential risks

Biologic subtypes as a predictor of local control in patients with brain metastases from breast cancer after stereotactic radiosurgery

Safety of nivolumab in combination with prior or concurrent radiation therapy in hepatocellular carcinoma

Radiotherapy for maxillary sinus carcinoma: dosimetric comparison of volumetric modulated arc therapy with 0° and 90° collimator intensity modulated radiation therapy

Comparison of ICRU 38 rectal reference point dose estimates with measured dose in vivo in cobalt-60 HDR brachytherapy for cervical cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer